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Background. Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal function and development, is im-
plicated in several neurodegenerative conditions. Preliminary data suggest that a reduction of BDNF concentrations may lead to
postchemotherapy cognitive impairment. We hypothesized that a single nucleotide polymorphism (rs6265) of the BDNF gene may
predispose patients to cognitive impairment. This study aimed to evaluate the effect of BDNF gene polymorphism on chemother-
apy-associated cognitive impairment.
Methods. Overall, 145 patients receiving chemotherapy for early-stage breast cancer (mean age: 50.8+8.8 y; 82.1% Chinese)
were recruited. Patients’ cognitive functions were assessed longitudinally using the validated Functional Assessment of Cancer
Therapy–Cognitive Function (v.3) and an objective computerized tool, Headminder. Genotyping was performed using Sanger se-
quencing. Logistic regression was used to evaluate the association between BDNF Val66Met polymorphism and cognition after
adjusting for ethnicity and clinically important covariates.
Results. Of the 145 patients, 54 (37%) reported cognitive impairment postchemotherapy. The Met/Met genotype was associated
with statistically significant lower odds of developing cognitive impairment (odds ratio [OR]¼ 0.26; 95% CI: 0.08–0.92; P¼ .036).
The Met carriers were less likely to experience impairment in the domains of verbal fluency (OR¼ 0.34; 95% CI: 0.12–0.90; P¼
.031) and multitasking ability (OR¼ 0.37; 95% CI: 0.15–0.91; P¼ .030) compared with the Val/Val homozygote. No associations
were observed between Headminder and the BDNF Val66Met polymorphism.
Conclusions. This is the first study to provide evidence that carriers of the BDNF Met allele are protected against chemotherapy-
associated cognitive impairment. Further studies are required to validate the findings.
Keywords: BDNF, breast cancer, cognition, genetics, rs6265.
Numerous studies have reported that patients with breast
cancer experience a moderate to severe degree of cognitive
impairment during chemotherapy.1,2 These cognitive changes
manifest as a spectrum of symptoms affecting memory,
concentration, and executive function. Although the exact
mechanism underlying chemotherapy-associated cognitive
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impairment is still under investigation, preliminary evidence
suggests that genetics may contribute to the increased sus-
ceptibility to the neurotoxic effects of chemotherapy.3 Limited
literature suggests that polymorphic expressions of apolipopro-
tein E (APOE) and catechol-O-methyltransferase (COMT)
increase the risk for cognitive impairment in patients with can-
cer.4,5 Breast cancer and lymphoma survivors who received
chemotherapy are more susceptible to poorer visual memory,
spatial ability, and psychomotor functioning if they are carriers
of the 14 allele of the APOE gene.4 In contrast, the polymor-
phism of the COMT gene (presence of the Val allele) was asso-
ciated with poorer attention, verbal fluency, and motor speed in
breast cancer survivors.5
Brain-derived neurotrophic factor (BDNF), a type of neurotro-
phin that is widely expressed in the brain, particularly in the pre-
frontal cortex and hippocampus, has been associated with
neuronal repair and survival, dendritic and axonal growth,
and long-term potentiation.6,7 Expressed by the BDNF gene, a
single nucleotide substitution (GA, rs6265) at nucleotide
196 in the coding sequence of BDNF results in an amino acid
change from valine to methionine at codon position 66,
which is found within the pro-region of BDNF.7,8 This change
has been linked to aberrant sorting of BDNF into secretory ves-
icles and decreased activity-dependent BDNF secretion. Given
the diverse effects of BDNF in the central nervous system, the
BDNF Val66Met single nucleotide polymorphism (SNP) has
been the focus in genetic studies of cognitive performance
and various neurodegenerative and mental disorders in the
noncancerous population.9 – 11 However, the relationship be-
tween the BDNF gene polymorphism and the occurrence of
chemotherapy-associated cognitive impairment has yet to be
evaluated. Hence, this study was designed to evaluate the as-
sociation between the BDNF Val66Met polymorphism and
chemotherapy-associated cognitive impairment within an
Asian breast cancer cohort.
Materials and Methods
Study Design
This was a prospective cohort study conducted at the National
Cancer Centre Singapore and KK Women’s and Children’s Hos-
pital, where 70% of all cancer patients in Singapore are treat-
ed. This study was approved by the SingHealth Institutional
Review Board.
Patients
Patients were eligible for the study if they fulfilled the following
inclusion criteria: (i) received a formal diagnosis of early-stage
breast cancer (stages I to III) by a medical oncologist, (ii) age of
at least 21 years, (iii) scheduled to receive chemotherapy
(anthracycline or taxane based), (iv) never had chemotherapy
and/or radiotherapy, and (v) understood either English or Chi-
nese. Patients were excluded if they were (i) diagnosed with
brain metastasis and/or any neuropsychiatric disorders that
might impair their cognitive function, (ii) symptomatically ill,
and (iii) physically or mentally incapable of giving written in-
formed consent. Brain imaging was performed for only stage
III breast cancer patients and all study participants were
assessed by the medical oncologists to confirm the absence
of brain metastasis and leptomeningeal disease. All patients
provided informed consent before recruitment.
Study Procedure
All recruited patients were assessed prospectively at 3 time
points: baseline (T1; prior to treatment), 6 weeks after the
start of treatment (T2), and 3 months after the start of treat-
ment (T3; end of chemotherapy). At the point of recruitment,
patients’ demographics, medical information, and medication
history were obtained from their electronic medical records
and through patient interviews. At each time point, patients
completed both objective and subjective neuropsychological
assessment tools and a set of patient-reported outcome ques-
tionnaires to assess their cognitive function, health-related
quality of life (HRQoL), anxiety, and fatigue.12 – 16 All data collec-
tion tools were available in English or Chinese and were admin-
istered by trained bilingual interviewers. Duration of the
interview was 40 min.
Study Tools
The following tools were used at each time point:
(i) Functional Assessment of Cancer Therapy–Cognitive Func-
tion (FACT-Cog) version 3: The FACT-Cog is used to measure
patients’ self-perceived cognitive decline.17 It evaluates
cognitive disturbances in the domains of mental acuity,
concentration, memory, functional interference, verbal flu-
ency, and multitasking ability. Patients rate the frequency
of cognitive impairment within the past 7 days on a
5-point Likert scale. Summing all item scores tabulates
the FACT-Cog summation score. Likewise, domain scores
are tabulated by summing the individual domain items.
Both the English and Chinese versions of FACT-Cog were
used in this study, and both versions have been validated
and have demonstrated equivalence and reliability.18
(ii) Headminder: This is a validated objective computerized
Web-based neuropsychological battery for examining pa-
tients’ cognitive function in 4 domains: processing speed,
response speed, memory, and attention.15 In view of the
multi-ethnicity of the study population, the non–language
dependent nature of Headminder served as a major ad-
vantage over the traditional pencil and paper neuropsy-
chological tests, as a proportion of the patients may not
be proficient in the English language.
(iii) Brief Fatigue Inventory (BFI): As fatigue is a known con-
founder of cognition, the BFI was used to rapidly assess
the severity and effect of cancer-related fatigue.12 It as-
sesses patients’ current level of fatigue and both the
usual and worst fatigue experienced within the last 24 h.
Six single items assess the extent to which fatigue has in-
terfered with different aspects of life (general activity,
mood, walking ability, normal work, relations with other
people, and enjoyment of life). The BFI is based on an
11-point scale, with 0 being “does not interfere” and 10
being “completely interferes.” The higher the score, the
higher the fatigue level.
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(iv) Beck Anxiety Inventory (BAI): As anxiety is a known confound-
er of cognition, the BAI was used to measure the severity of
anxiety in patients. The BAI is a validated questionnaire that
describes common symptoms associated with anxiety.13
Patients rate the severity of anxiety on a scale of 0 to 3,
with 0 being “not at all” and 3 being “severe.” Each item
score is summed to yield a total score ranging from 0 to
63. The higher the score, the greater the level of anxiety.
(v) European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ-C30):
The EORTC QLQ-C30 is a validated questionnaire developed
to assess cancer patients’ HRQoL in the past 1 week.19 It
incorporates 5 functional scales (cognitive, emotional,
physical, role, and social), 3 symptom scales (pain, fatigue,
nausea and vomiting), and a global health and QoL scale.
The remaining items assess symptoms reported by cancer
patients (appetite loss, constipation, diarrhea, dyspnea,
and sleep disturbance) and financial effects. All scales
and single items are linearly transformed into a scale of
0 to 100. The higher the score on the functional and QoL
scales, the better the functional status and HRQoL. In con-
trast, the higher the score on the symptom scales, the
higher the level of symptoms experienced.
Genotyping
A 10-mL sample of whole blood was drawn from each partici-
pant into an ethylene-diamine-tetra-acetic acid (EDTA) tube
upon recruitment. The sample was centrifuged at 2500 rpm
for 10 min within 30 to 40 min of collection. The buffy coat
was aliquoted and stored aseptically at 2808C until analysis.
Genomic DNA from the buffy coat was subsequently isolated
using the QIAamp DNA Blood Mini Kit (Qiagen). The region
containing the BDNF Val66Met polymorphism (rs6265) was
amplified by polymerase chain reaction (PCR) using specific
and optimized primers. The following primers were used:
5′-GGACTCTGGAGAGCGTGAA-3′ (forward) and 5′-CGTGTACAA
GTCTGCGTCCT-3 (reverse). Genotyping of the PCR products was
subsequently performed by automated Sanger sequencing
using a 3730xl DNA Analyzer (Applied Biosystems). Genotyping
was performed for both the forward and reverse DNA strands
for quality control purposes. Samples were identified only by
codes, and genotyping was blindly performed without the
knowledge of clinical outcomes by AITbiotech.
Endpoints
The primary endpoint, determined a priori, was the association
between the BDNF Val66Met polymorphism and chemothera-
py-associated cognitive impairment as assessed by the global
FACT-Cog score. Secondary endpoints included the associations
of the BDNF Val66Met polymorphism with the individual cogni-
tive domains of FACT-Cog and Headminder, and the EORTC
QLQ-C30 multi-item scales and single-item measures.
Defining Cognitive Impairment
Cognitive changes were assessed using FACT-Cog and Head-
minder. Impairment in self-perceived cognitive function was
defined as a reduction of≥10.6 points in the FACT-Cog summa-
tion score during T2 or at the end of chemotherapy (T3) com-
pared with the baseline value. This reduction represents the
minimal clinically important difference that is considered as
clinically significant in our cohort.20 To establish whether a pa-
tient had cognitive impairment in a particular cognitive domain,
the patient’s score at T2 or T3 must have been at least 15%
lower than his or her baseline score.
To assess whether a patient had cognitive impairment with
Headminder, a reliable change index was calculated based on
the repeated normative mean and standard error of the differ-
ence to adjust for the practice effect. Patients were classified as
having an impairment in each of the Headminder domains if
the reliable change index score was lower than 21.5.
Statistical Analysis
Descriptive statistics were used to summarize the demographic
and clinical characteristics of the patients. Demographic data
and questionnaire scores were compared between cases and
controls using the independent-sample t-test or the Mann–
Whitney U-test for normally distributed and nonnormally dis-
tributed data, respectively. The chi-square test was used to
identify differences in categorical demographic data between
the 2 groups. Deviation of the genotypes from Hardy–Weinberg
equilibrium was calculated using the chi-square test with one
degree of freedom. Binary logistic regression was subsequently
used to evaluate the associations between the BDNF Val66Met
polymorphism (rs6265) and chemotherapy-associated cogni-
tive impairment. Results are reported as odds ratios (ORs)
and 95% confidence intervals (CIs). Documented known con-
founders of chemotherapy-associated cognitive impairment
(age, anxiety status, fatigue status, menopausal status, che-
motherapy regimens, education level, and insomnia) and race
were included in the logistic regression model.21,22 For anxiety
(BAI total score), fatigue (BFI total score), and insomnia (EORTC
QLQ-C30), the scores of these behavioral symptoms that corre-
sponded to the time point for which cognitive impairment oc-
curred were used in the logistic regression model. In addition,
variables that achieved P≤ .1 in the univariate analysis were in-
cluded in the logistic regression model. Linear regression was
performed to delineate the associations between the EORTC
QLQ-C30 multi-item scales and single-item measures and the
BDNF Val66Met polymorphism, adjusting for race. All statistical
tests were 2-sided, and P, .05 was considered statistically sig-
nificant. Statistical analyses were performed using IBM’s Statis-
tical Package for the Social Sciences (version 22). Post-hoc
power analysis for the primary endpoint was calculated using
Quanto version 1.2.4.
This article conforms to the reporting guidelines of Strength-
ening the Reporting of Genetic Association Studies.23
Results
Patient Demographics
The final analysis included 145 patients with breast cancer
(Table 1). Their mean age+SD was 50.8+8.8 years. Patients
were predominantly Chinese (82.1%), and 84.8% had received
secondary school education and above. Half of the patients
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(49.7%) were diagnosed as having stage II breast cancer,
and most participants (94.5%) were ambulatory without
restrictions on activities, as reflected by an Eastern Cooperative
Oncology Group performance status of 0 at baseline assess-
ment. Ninety-four patients (64.8%) received an anthracycline-
based chemotherapy regimen.
Genotype and Allele Frequencies
All 145 patients were successfully genotyped for the BDNF SNP
(rs6265). Genotype frequencies were in Hardy–Weinberg equi-
librium (P¼ .75). The Val/Met genotype accounted for approxi-
mately one-half of the observed genotypes (51.0%). Both the
Val allele and the Met allele were present in approximately
equal frequencies (Table 2).
Association of BDNF Genotypes with
Chemotherapy-Associated Cognitive Impairment
Cognitive function at baseline is described in Supplementary
Table S1. On the basis of the minimal clinically important differ-
ence of the FACT-Cog summation score, 54 patients experienced
clinically significant self-perceived cognitive impairment, where-
as the remaining 91 patients did not. Univariate analysis identi-
fied “working status” as a covariate between the 2 groups,
and this variable was subsequently adjusted in the final logistic
regression model. After adjusting for clinically documented con-
founders and working status, it was observed that the patients
with the Met homozygous genotype had significantly lower odds
of developing cognitive decline (OR¼ 0.26; 95% CI: 0.08–0.92;
P¼ .036) than the patients with the Val homozygous genotype
(Fig. 1A). A post-hoc power analysis calculated based on the
observed allele frequency, sample size, and observed OR for
the primary endpoint showed the power of the study to
be 85%. When comparing the cognitive outcomes of Met
carriers (Val/Met and Met/Met) and the Val/Val homozygote, no
significant association was established (OR¼ 0.40; 95% CI:
0.16–1.03; P¼ .056).
Among the 6 cognitive domains, the presence of the Val/Met
heterozygous genotype was associated with lower odds (OR¼
0.34; 95% CI: 0.13–0.90; P¼ .030) of impairment in the multi-
tasking ability domain, whereas the Met/Met homozygous ge-
notype exerted a protective effect (OR¼ 0.26; 95% CI: 0.07–
0.96; P¼ .043) for verbal fluency compared with the Val/Val
homozygous genotype (Fig. 2A; Supplementary Table S2). Over-
all, the Met carriers were less likely to experience impairment in
the domains of verbal fluency (OR¼ 0.34; 95% CI: 0.12–0.90;
P¼ .031) and multitasking ability (OR¼ 0.37; 95% CI: 0.15–
0.91; P¼ .030) compared with the Val/Val homozygote. No as-
sociations were observed between the cognitive domains of
Headminder and the BDNF Val66Met polymorphism (Supple-
mentary Table S4).
In a subgroup analysis involving patients aged ≥55 years
(n¼ 54), carriers of the Met allele (OR¼ 0.07; 95% CI: 0.01–
0.83; P¼ .035) were associated with decreased odds of cogni-
tive impairment (as defined by the FACT-Cog summation score)
compared with the Val/Val homozygous group. In particular,
expression of the Val/Met heterozygous genotype conferred
a protective effect against cognitive decline (OR¼ 0.06; 95%
CI: 0.01–0.77; P¼ .031) (Fig. 1B). In addition, the Val/Met het-
erozygous genotype was associated with lower odds of impair-
ment for the multitasking ability domain (OR¼ 0.09; 95% CI:
0.01–0.90; P¼ .040) (Fig. 2B; Supplementary Table S3).
Association of BDNF Genotypes with the EORTC QLQ-C30
Scales
Among the multi-item scales and single-item measures of
EORTC QLQ-C30, the social functioning scale (beta: 212.14;
95% CI: 222.65 to 21.63; P¼ .02) and dyspnea item scale
(beta: 29.23; 95% CI: 217.54 to 20.92; P¼ .03) were found
to be significantly associated with the Met/Met and Val/Met ge-
notypes, respectively, at T2 compared with the Val/Val homozy-
gous group. No significant associations were observed for the
global health status and the remaining EORTC QLQ-C30 scales
(Supplementary Table S5).
Table 1. Demographics and clinical information of the patients
(N ¼ 145)
n (%)
Age, y, mean+SD 50.8+8.8
Ethnicity Chinese 119 (82.1)
Malay 15 (10.3)
Indian 7 (4.8)
Othersa 4 (2.8)
Education Primary school 22 (15.2)
Secondary school 70 (48.3)
Pre-university 29 (20.0)
Graduate/
postgraduate
24 (16.6)
Marital status Single 31 (21.4)
Married 102 (70.3)
Divorced 10 (6.9)
Widowed 2 (1.4)
Working status Currently working 82 (56.6)
Currently not working 63 (43.4)
Cancer stage I 32 (22.1)
II 72 (49.7)
III 41 (28.3)
ECOG performance status 0 137 (94.5)
1 8 (5.5)
Menopausal status Pre-menopausal 74 (51.0)
Post-menopausal 71 (49.0)
Chemotherapy regimen Anthracycline-based 94 (64.8)
Taxane-based 51 (35.2)
Behavioral symptoms,
mean+SD
Baseline fatigue (BFI total
score)b
1.6+1.7
Baseline anxiety (BAI total
score)c
6.7+6.1
Baseline insomnia scored 23.1+26.9
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aOthers includes 1 Burmese and 3 Filipinos.
bBFI total score is 10 points.
cBAI total score is 63 points.
dInsomnia subscale total score is 100 points.
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Discussion
We evaluated the genetic association between BDNF Val66Met
polymorphism (rs6265) and chemotherapy-associated cogni-
tive impairment in Asian patients receiving chemotherapy for
early-stage breast cancer. We found that the BDNF Val66Met
polymorphism was associated with decreased susceptibility
to self-perceived cognitive decline, predominantly in the do-
mains of verbal fluency and multitasking ability. Notably, the
Met allele was found to confer a protective effect against self-
perceived cognitive impairment in older patients with breast
cancer. In addition, the BDNF Val66Met polymorphism was as-
sociated with poor EORTC QLQ-C30 social functioning and
fewer dyspnea symptoms.
In the literature, whether the Met allele represents a factor
that increases susceptibility or confers protection against cog-
nitive impairment and various neuropsychiatric disorders re-
mains controversial. In the context of human cognition, initial
genetic association studies showed that the Met allele was
associated with reduced memory performance in populations
of healthy young individuals and schizophrenic patients.24 – 26
However, it is important to emphasize that these studies pos-
sess major limitations. For example, most of these studies are
cross-sectional in nature and did not evaluate changes in cog-
nition over time. Furthermore, the study populations included
are very heterogeneous, and these studies are also limited by
relatively small sample sizes.
In recent years, a growing amount of literature has suggest-
ed that elderly patients who are Met allele carriers are at lower
risk for cognitive impairment.27 – 29 One longitudinal study in-
volving 384 patients with Parkinson disease found that the
Met allele carriers experienced less decline in execution func-
tioning than those who were Val/Val homozygotes.29 The re-
sults are consistent with those of other studies in which
healthy elderly people presenting Met alleles exhibited better
working memory and task-switching performances.27,28
Although there is evidence to suggest that older cancer
patients may suffer from a higher rate of cognitive decline as
explained by the “accelerated aging” hypothesis, our findings
suggest that the Met allele could render protection against
such age-related cognitive decline.2 It was suggested that car-
riers of the BDNF Met allele can attenuate the negative effects
of aging on working memory performance starting in the third
decade of life, indicating that the SNP can lead to an increase of
BDNF secretion and mask any age-related alterations of cogni-
tion.30 Another study has also suggested that elderly people
who are carriers of the Met allele have larger brain volumes in
the hippocampus and bilateral cerebellum, which contribute to
memory and decision making, with smaller volumes in the right
occipital-temporal lobe, and thus experience less arousal inter-
ference. The authors therefore hypothesized that the SNP con-
tributes not only to cognitive but also to anatomical variation.28
Confirmatory studies are required to validate this hypothesis.
An understanding of the neurobiology behind BDNF may
improve our understanding of how BDNF mutations may affect
cognitive function after chemotherapy. In the human brain,
BDNF is synthesized as a precursor called proBDNF, which is
subsequently cleaved to produce the mature BDNF. It must
be noted that proBDNF binds preferentially to p75 neurotrophin
receptor and activates the apoptotic pathways, whereas
mature BDNF binds specifically to the receptor of tropomyosin-
related kinase B and leads to neuronal survival, differentiation,
and plasticity.8 Activity-dependent secretion is the major
Table 2. Genotype and allele frequencies of the BDNF Val66Met polymorphism (rs6265)
Genotype/Allele Frequencies, n (%) Population, n (%)
Chinese Malay Indian Othersa Pooled Asians, N (%)
119 15 7 4 145
GG (Val/Val) 26 (21.8) 5 (33.3) 4 (57.1) 3 (75.0) 38 (26.2)
AG (Val/Met) 63 (52.9) 7 (46.7) 3 (42.9) 1 (25.0) 74 (51.0)
AA (Met/Met) 30 (25.2) 3 (20.0) 0 (0.0) 0 (0.0) 33 (22.8)
G (Val) allele 115 (48.3) 17 (56.7) 11 (78.6) 7 (87.5) 150 (51.7)
A (Met) allele 123 (51.7) 13 (43.3) 3 (21.4) 1 (12.5) 140 (48.3)
aOthers includes 1 Burmese and 3 Filipinos.
Fig. 1. (A) Association between the BDNF Val66Met polymorphism
(rs6265) and the summation score of FACT-Cog in all patients
(N ¼ 145) and (B) within the subgroup of patients aged ≥55 years
(n¼ 54). *P, .05.
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pathway for BDNF release from neurons, and proBDNF has been
identified to be the predominant form of BDNF released via this
activity-dependent pathway.31 On the basis of the biological
consequences of the BDNF Val66Met polymorphism, it was hy-
pothesized that the impaired intracellular trafficking resulting
from the polymorphism could lead to a reduction in the secre-
tion and release of pro-apoptotic proBDNF. This might be ben-
eficial in Met allele carriers under circumstances in which a
considerable subpopulation of neurons is undergoing apoptosis
due to other external factors such as chemotherapy.32 Chemo-
therapeutic agents have been well established to generate re-
active oxygen species in patients during systemic cancer
treatment.33 For example, doxorubicin mediates neurotoxicity
in the brain indirectly by stimulating production of tumor necro-
sis factor–a, which triggers the synthesis of inflammatory cyto-
kines that leads to downstream generation of reactive oxygen
species, thereby inducing neuronal apoptosis.34 Taken together,
it can be postulated that the reduction of pro-apoptotic
proBDNF secretion in Met allele patients may diminish neuronal
apoptosis. This would result in a smaller extent of cognitive
decline, particularly when patients are experiencing neuronal
cell death induced by the chemotherapeutic agents during
treatment. Although the exact influence of BDNF Val66Met
polymorphism on neuroprotection awaits confirmation, its ef-
fect on the perturbation of cognitive function is evident from
these prior studies and our present findings.
Based on the current recommendations of the International
Cognition and Cancer Task Force, both subjective and objective
cognitive assessments should be incorporated into studies to
evaluate cognitive function in patients with cancer.35 In this
study, both methods were utilized. Although positive associa-
tions were only established between the BDNF Val66Met
polymorphism and self-perceived cognitive impairment
measured by FACT-Cog, associations were not observed with
the computerized neuropsychological tool (Headminder). This
disparity may largely be attributable to the poor correlation
between the 2 measures of cognition.35 – 38 Although neuropsy-
chological assessments are acknowledged as the gold stan-
dard for the evaluation of cognitive function, it must be
accentuated that these tests have not been evaluated on
how well they relate to “real-world” skills and performance.39
There are also additional concerns that these assessments
may not be sensitive to detect subtle cognitive impairment in-
curred by patients.40 While studies have suggested that self-
perceived cognitive impairment may indicate the presence of
other emotional distress elements more than cognitive impair-
ment, it is still unclear whether the emotional distress is attrib-
uted to the existing cognitive issues or vice versa. Furthermore,
subjective cognitive impairment has shown to be associated
with brain structural changes among individuals who had
normal neuropsychological test performance.41,42 Hence, we
highly value the measures provided by subjective reporting
using patient-reported outcomes because the tool provides in-
sights into how cognitive deficits impact patients’ QoL and daily
functioning, which are useful in detecting subtle cognitive
changes.39,40,43
In this study, there is an absence of association between the
global health status measured using the EORTC QLQ-30 and
BDNF Val66Met polymorphism, and this finding is not unexpect-
ed. The EORTC QLQ-C30 is a generic tool that evaluates the
impact of cancer and its treatment on patients’ functional
performance, symptom burden, and overall HRQoL. This is dif-
ferent from FACT-Cog, which is a specific patient-reported out-
come tool that assesses the nature and severity of cognitive
Fig. 2. (A) Association between the BDNF Val66Met polymorphism (rs6265) and the multitasking and verbal fluency domains of FACT-Cog in all
patients (N¼ 145) and (B) within the subgroup of patients aged ≥55 years (n¼ 54). *P, .05.
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deficits and the impact of such impairment on patients’ QoL.
The negative findings strengthen our hypothesis that the asso-
ciation between the BDNF Val66Met polymorphism and cogni-
tive function is attributed to changes in cognitive function and
not to changes in overall QoL.
The strengths of this study include its sufficiently powered
sample size (based on the primary endpoint), pretreatment
and longitudinal assessment of cognitive function (over 3 time
points), and behavioral symptoms (anxiety, fatigue, and insom-
nia), adjustment for well-known documented confounders of
cognition, and the use of validated tools to evaluate cognition.
Chemotherapy-associated cognitive impairment is regarded as
a multifactorial complex phenotype; therefore, accounting for
clinical, behavioral, or environmental factors associated with
such a complex phenotype would improve the precision of the
results.28,44 However, one major challenge of all cognitive studies
is the issue of multiple testing. To minimize problems associated
with multiple testing, the summation score of the FACT-Cog was
used as the primary endpoint, and the secondary endpoints
were regarded as exploratory analyses. Hence, the P-value was
not adjusted for multiple testing, and readers should interpret
our findings with caution. In addition, this study focused on
early cognitive changes that occurred during the course of che-
motherapy. It is unknown whether these findings are applicable
to late-onset cognitive impairment postchemotherapy.
In conclusion, this study is the first, to the best of our knowl-
edge, to show the protective effect of the BDNF Val66Met
polymorphism against chemotherapy-associated cognitive im-
pairment in an Asian population with breast cancer. The current
findings provide preliminary insights into the role of this SNP in
the manifestation of chemotherapy-associated cognitive im-
pairment. With further validation of these findings, a better un-
derstanding of the mechanisms underlying this adverse outcome
could be achieved. Imaging studies should be incorporated in fu-
ture analyses to further understand whether the SNP contributes
to the alteration of brain anatomy. In this way, effective and
timely rehabilitation and management strategies can be used
in susceptible patients to avert or minimize the occurrence of
this adverse outcome.
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